SELLAS announces FDA rare pediatric disease designation for its leukemia treatment

seekingalpha10-15

wildpixel/iStock via Getty Images SELLAS Life Sciences Group (NASDAQ:SLS) announced that the U.S. FDA has granted Rare Pediatric Disease Designation to Galinpepimut-S, an immunotherapeutic targeting ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475685829?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277148522/image_1277148522.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-15 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475685829","market":"sh","top_or_hot":-1,"title":"SELLAS announces FDA rare pediatric disease designation for its leukemia treatment","media":"seekingalpha","content":"<div>\n<p>wildpixel/iStock via Getty Images  SELLAS Life Sciences Group (NASDAQ:SLS) announced that the U.S. FDA has granted Rare Pediatric Disease Designation to Galinpepimut-S, an immunotherapeutic targeting ...</p>\n\n<a href=\"https://seekingalpha.com/news/4160126-sellas-announces-fda-rare-pediatric-disease-designation-for-its-leukemia-treatment\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SELLAS announces FDA rare pediatric disease designation for its leukemia treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSELLAS announces FDA rare pediatric disease designation for its leukemia treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4160126-sellas-announces-fda-rare-pediatric-disease-designation-for-its-leukemia-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>wildpixel/iStock via Getty Images  SELLAS Life Sciences Group (NASDAQ:SLS) announced that the U.S. FDA has granted Rare Pediatric Disease Designation to Galinpepimut-S, an immunotherapeutic targeting ...</p>\n\n<a href=\"https://seekingalpha.com/news/4160126-sellas-announces-fda-rare-pediatric-disease-designation-for-its-leukemia-treatment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_NQ","symbol_name":"NQ100指数","start_time":0,"source_url":"https://seekingalpha.com/news/4160126-sellas-announces-fda-rare-pediatric-disease-designation-for-its-leukemia-treatment","article_id":"2475685829","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277148522/image_1277148522.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475685829","pubTimestamp":1728999295,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"wildpixel/iStock via Getty Images  SELLAS Life Sciences Group  announced that the U.S. FDA has granted Rare Pediatric Disease Designation to Galinpepimut-S, an immunotherapeutic targeting Wilms Tumor-1, for the treatment of pediatric acute myeloid leukemia. The FDA grants Rare Pediatric Disease Designation for serious","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLS":"SELLAS Life Sciences Group Inc.","SQQQ":"纳指三倍做空ETF","BK4139":"生物科技",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","QID":"纳指两倍做空ETF"},"translate_title":"SELLAS宣布其白血病治疗获得FDA罕见儿科疾病指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":0.9,".IXIC":0.69,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"wildpixel/iStock via Getty Images  SELLAS Life Sciences Group (NASDAQ:SLS) announced that the U.S. FDA has granted Rare Pediatric Disease Designation to Galinpepimut-S, an immunotherapeutic targeting Wilms Tumor-1, for the treatment of pediatric acute myeloid leukemia. The FDA grants Rare Pediatric Disease Designation for serious","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475685829"}